kringle-pharmaCo., Ltd.

NEWS

notice

Dec 28, 2020 Notice

Kringle Pharma, a late clinical-stage biopharmaceutical company developing recombinant human hepatocyte growth factor for incurable diseases such as acute spinal cord injury and ALS, announces the closing of its initial public offering on the Tokyo Stock Exchange Mothers market.

Kringle Pharma, a late clinical-stage biopharmaceutical company developing recombinant human hepatocyte growth factor for incurable diseases such as acute spinal cord injury and ALS, announces the closing of its initial public offering on the Tokyo Stock Exchange Mothers market.